

FINANCIAL TEAR SHEET

CORPORATE PROFILE

iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. Our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias.


We have created a unique platform, ZIO by iRhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

STOCK INFORMATION

IRTC (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$44.64
Change (%)	▼ 0.47 (1.04%)
Volume	84,334
52 Week Low	\$22.16
Market Cap	\$1,025,346,105
Rolling EPS	-1.10
PE Ratio	0
Shares Outstanding	22,729,907

Data as of 08/17/17 12:55 p.m. ET



RECENT NEWS

Date	Title
08/02/17	iRhythm Technologies Announces Second Quarter 2017 Financial Results
07/19/17	iRhythm Technologies to Report Second Quarter 2017 Financial Results on August 2, 2017
07/19/17	iRhythm Technologies Names Former Blue Cross Blue Shield of California CEO Bruce G. Bodaken and Duke University Chancellor Emeritus Ralph Snyderman, M.D. to its Board of Directors

UPCOMING EVENTS

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
08/16/17	8-K
08/08/17	4
08/08/17	4
08/07/17	10-Q

Data provided by Nasdaq. Minimum 15 minutes delayed.